Bone marrow-derived mesenchymal stromal cells(The University of Queensland)(Bone marrow-derived mesenchymal stromal cells(The University of Queensland))

概要

基本信息

药物类型

间充质干细胞疗法

别名

bone marrow-derived mesenchymal stromal cells(The University of Queensland)、Bone-marrow derived MSCs(The University of Queensland)

靶点-

作用机制

细胞替代物

治疗领域

免疫系统疾病

在研适应症

同种异体移植排斥反应

非在研适应症

扩张型心肌病冠心病特发性心肌病+ [2]

原研机构

The University of Queensland

在研机构

The University of Queensland

非在研机构

Hospital General Universitario Gregorio Marañón

Pharmicell Co., Ltd.

最高研发阶段临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

9

项与 Bone marrow-derived mesenchymal stromal cells(The University of Queensland) 相关的临床试验

NCT05559801

/ Not yet recruiting临床1/2期IIT

A Phase 1/2 Study to Examine the Safety and Preliminary Efficacy of Mesenchymal Stromal Cells on Linear Growth and Bone Health Parameters in Children With Type 3 Osteogenesis Imperfecta (OI)

This is a Phase 1/2 study to determine the safety and efficacy of allogeneic (third party), bone-marrow derived mesenchymal stromal cells (MSCs) for the treatment of Osteogenesis Imperfecta (OI) Type 3. It will evaluate this by looking at whether there are treatment related infusion reactions, and assessing linear growth rates and bone health, both of which are impaired in patients ages 3-10 with Osteogenesis Imperfecta Type 3. This is a single-site non-randomized clinical trial, that will take place at Children's Healthcare of Atlanta (CHOA) at Egleston and Emory Children's Center.

开始日期2025-02-01

申办/合作机构

Emory University

NCT05288725

/ Unknown status临床1/2期IIT

A Study to Evaluate the Safety, and Efficacy of Minimally Manipulated Autologous Bone Marrow Aspirate to Treat Knee Osteoarthritis in Patients

The study is a multicentered, randomized, double-blinded, placebo-controlled study conducted on the unilateral knee of 120 patients. The study compares the effectiveness of an injection of a mesenchymal stem cell preparation from autologous bone marrow aspirate (BMA) to a corticosteroid control for knee osteoarthritis. WOMAC, VAS pain scores, and MRI will be used for assessment. The study will be conducted at 3 sites in the United States.

开始日期2022-08-01

申办/合作机构

Next Generation Regenerative Medicine LLC

ACTRN12620000840987

/ Recruiting临床1期IIT

Phase I trial on safety and tolerability of bone-marrow derived mesenchymal stromal cells (MSC) for deteriorating COVID-19 pneumonia

开始日期2020-05-05

申办/合作机构-

100 项与 Bone marrow-derived mesenchymal stromal cells(The University of Queensland) 相关的临床结果

登录后查看更多信息

100 项与 Bone marrow-derived mesenchymal stromal cells(The University of Queensland) 相关的转化医学

登录后查看更多信息

100 项与 Bone marrow-derived mesenchymal stromal cells(The University of Queensland) 相关的专利（医药）

登录后查看更多信息

5

项与 Bone marrow-derived mesenchymal stromal cells(The University of Queensland) 相关的文献（医药）

2021-04-01·ERJ open research

Endobronchial autologous bone marrow–mesenchymal stromal cells in idiopathic pulmonary fibrosis: a phase I trial

Article

作者: Cordovilla, Rosa ; Villaron, Eva ; Nuñez-Córdoba, Jorge ; González-Ruiz, José María ; Barrueco, Miguel ; Andreu, Enrique ; Zulueta, Javier J ; Prósper, Felipe ; De-Torres, Juan ; Alcaide, Ana B ; Pueyo, Jesús ; Campo, Arantza ; Sanchez-Guijo, Fermín ; Ocón, María M

Rationale:

Idiopathic pulmonary fibrosis (IPF) has a dismal prognosis. Mesenchymal stromal cells (MSCs) have shown benefit in other inflammatory diseases.

Objectives:

To evaluate the safety and feasibility of endobronchial administration of bone marrow autologous MSCs (BM-MSC) in patients with mild-to-moderate IPF.

Methods:

A phase I multicentre clinical trial (ClinicalTrials.govNCT01919827) with a single endobronchial administration of autologous adult BM-MSCs in patients diagnosed with mild-to-moderate IPF. In a first escalating-dose phase, three patients were included sequentially in three dose cohorts (10×106, 50×106and 100×106cells). In a second phase, nine patients received the highest tolerated dose. Follow-up with pulmonary function testing, 6-min walk test and St George's Respiratory Questionnaire was done at 1, 2, 3, 6 and 12 months, and with computed tomography at 3, 6 and 12 months.

Results:

21 bone marrow samples were obtained from 17 patients. Three patients were excluded from treatment due to chromosome aberrations detected in MSCs after culture, and one patient died before treatment. Finally, 13 patients received the BM-MSC infusion. No treatment-related severe adverse events were observed during follow-up. Compared to baseline, the mean forced vital capacity showed an initial decline of 8.1% at 3 months. The number of patients without functional progression was six (46%) at 3 months and three (23%) at 12 months.

Conclusions:

The endobronchial infusion of BM-MSCs did not cause immediate serious adverse events in IPF patients, but a relevant proportion of patients suffered clinical and/or functional progression. Genomic instability of BM-MSCs during culture found in three patients may be troublesome for the use of autologous MSCs in IPF patients.

2021-01-01·The Journal of biological chemistry

Withdrawal: Bone marrow stromal cell-derived growth inhibitor inhibits growth and migration of breast cancer cells via induction of cell cycle arrest and apoptosis

Article

作者: Wang, Tao ; Wang, Chunmei ; Chen, Taoyong ; Xia, Dajing ; Chen, Guoyou ; Li, Nan ; Wan, Tao ; Cao, Xuetao

2020-06-01·The Journal of biological chemistry

Expression of Concern: Bone marrow stromal cell-derived growth inhibitor inhibits growth and migration of breast cancer cells via induction of cell cycle arrest and apoptosis.

Article

100 项与 Bone marrow-derived mesenchymal stromal cells(The University of Queensland) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
肺移植排斥反应	临床2期	澳大利亚	The University of Queensland	2020-03-31
同种异体移植排斥反应	临床2期	澳大利亚	The University of Queensland	2017-04-21
冠心病	临床2期	西班牙	Hospital General Universitario Gregorio Marañón	2013-03-31
特发性心肌病	临床2期	西班牙	Hospital General Universitario Gregorio Marañón	2013-03-31
扩张型心肌病	临床2期	西班牙	Hospital General Universitario Gregorio Marañón	2013-03-01
酒精性肝硬化	临床1期	美国	Pharmicell Co., Ltd.	2019-06-20

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03818737 (MILES, CTgov)	临床3期	膝关节炎	475	Bone Marrow Derived MSCs (Bone Marrow Derived MSCs)	襯繭選選鏇獵積餘遞鏇(鹽願獵糧鏇夢衊艱繭鏇) = 膚鹹衊築鬱廠衊鏇顧獵艱構遞觸網衊網觸築觸 (艱觸醖選窪憲廠廠簾壓, 簾夢觸願鑰鹹齋網願衊 ~ 窪窪餘夢選壓餘膚選醖) 更多	-	2023-07-27
				Adipose-derived MSCs (Adipose-derived MSCs)	襯繭選選鏇獵積餘遞鏇(鹽願獵糧鏇夢衊艱繭鏇) = 構襯襯憲選顧衊鑰範鑰艱構遞觸網衊網觸築觸 (艱觸醖選窪憲廠廠簾壓, 膚衊壓壓衊蓋艱繭願鹹 ~ 獵餘製艱夢範願夢鬱遞) 更多
HOVON-113 (EHA2022) 人工标引	临床3期	类固醇难治性移植物抗宿主病	41	Mesenchymal stromal cell	顧鹽壓構糧憲繭鹹齋積(繭壓顧蓋壓網築製願選) = 齋鑰鹹構衊憲壓積壓願網遞鑰築廠觸衊鬱衊繭 (網顧夢遞願顧醖遞醖獵 ) 更多	不佳	2022-05-12
				placebo	顧鹽壓構糧憲繭鹹齋積(繭壓顧蓋壓網築製願選) = 醖窪鑰顧淵艱憲願獵糧網遞鑰築廠觸衊鬱衊繭 (網顧夢遞願顧醖遞醖獵 ) 更多